C. Difficile

Ferring Pharmaceuticals and Rebiotix reported results from a trial on their therapy, RBX2660, which shows promise as a Clostridioides difficile infection (CDI) treatment.

A study looked at hospital admissions of Medicare patients and saw a large percentage of recurrent Clostridioides difficile infections (rCDI) as the primary diagnosis.

An effort to increase stewardship showed that 5-day and 10-day prescription stop dates for antibiotics did little to influence actual therapy length and outcomes.

A large retrospective analysis of Medicare patients offers a glimpse of the incidence rates of this patient population and the burdens associated with it.

A meta-analysis suggest the 2 first-line C diff therapies provide similar outcomes, yet differ in recurrent infection risk.

Cancer patients are more than twice as likely to acquire hospital-associated Staphylococcus aureus bacteraemia (HA-SAB) and Clostridioides difficile infection (HA-CDI) than others, a new study from Australia found.

The proportion of cases with CDI in perforated appendicitis was found to be greater in comparison to the non-perforated cases.

Treatment with rifampin shows it can increase the chances for recurrent Clostridium difficile (C diff) infection according to investigators in Mexico.

The discovery of C diff’s ability to harness heme to shield itself from the body’s immune responses hopefully brings a new dimension to the fight against the damaging pathogen.

CDI prevalence among those hospitalized with a COVID-19 infection was not found to be increased despite more use of antibiotics.

Experts discuss the bacteria’s transmission in the community setting, how to reduce disease and economic burdens, and ways to improve quality of life for patients.

A study of more than 400 hospitals offers takeaways for creating antibiotic stewardship programs in hospitals around the country.

With labs blinding a specific panel, a C diff diagnosis can be masked and missed.

Updated review and meta-analysis identifies the classes of antibiotics most strongly linked to healthcare facility-associated Clostridioides difficile infection.

This prognostic marker might not be an adequate reason to test for Clostridium difficile in hospitalized patients.

Oral vancomycin prophylaxis was found by a small study to prevent C diff infection in thoracic transplant patients.

The study determined that acid-base disturbances like can influence the risk of a C diff infection after cardiac surgery is performed

Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections and the clinical spectrum ranges from asymptomatic colonization to toxic megacolon and fulminant colitis.

Infection control efforts to combat hospital-onset Clostridioides difficile infection may be better spent on health care workers’ hand hygiene compliance and environmental cleaning than on visitor contact precautions, a new study suggests.

Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.

Rates of serious clinical complications of Clostridioides difficile infection rose as the number of recurrent infections increased, underscoring the importance of advancing new treatments to prevent recurrence of the disease, a recent study in SAGE Open Medicine found.

According to one new study, proton-pump inhibitors (PPI) exposure demonstrated a moderate increase in the risk of community-acquired C diff infection.

Clostridioides difficile thrives in an environment of inflammation which found that inflammation provides nutrients for C. diff and creates an inhospitable environment for competing bacteria.

Investigators said their paper was the first systematic review and meta-analysis of C diff infection diagnostic methods in Korea.

An orally administered adsorbent to prevent antibiotic disruption of intestinal flora enters phase 3 trial against clostridium difficile (C diff) in patients with hematologic malignancies.

Contemporary care guidelines for this bacterium in geriatrics needs to be followed more closely, one study found.

Empiric broad-spectrum antimicrobial therapy, including coverage of MRSA and Pseudomonas aeruginosa, is generally recommended for healthcare-associated infections.

The bowel resting strategy might reduce switching from metronidazole to vancomycin among patients with Clostridioides difficile infection, but it might not reduce mortality or recurrence, a new study found.

Therapies in the pipeline to treat C. difficile and closing thoughts on what is most exciting, in regards to better prevention and management of the condition, moving forward.